

Docket No. 206704US0PCT/sdc

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hisaaki CHAKI, et al.

SERIAL NO: 09/830,559

GAU: 1614

FILED: May 7, 2001

EXAMINER:

NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

## REFERENCES

- ☒ The applicant(s) wish to make of record the references, some of which are cited in the attached International Search Report listed on the attached form PTO-1449. Copies of reference(s) AL through AP and AT through AZ, have been received by the U.S. PCT Receiving Office from the International Bureau as acknowledged in the Notification of Acceptance.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

## RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).


## CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

## DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon  
Registration No. 24,618WILLIAM E. BLAUMANN  
REGISTRATION NUMBER 30,996

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 10/98)RECEIVED  
SEP 17 2001  
TECH CENTER 1600/2900


MAR 28 2002

RECEIVED

TECH CENTER 1600/2900

NOV 05 2002

RECEIVED



RECEIVED  
SEP 17 2001  
TECH CENTER 1600/2900  
PAGE 1 OF 1

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 206704US0PCT		SERIAL NO. 09/830,559	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Hisaaki CHAKI, et al.			
				FILING DATE May 7, 2001		GROUP 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,852,046	12/22/98	H.-J. LANG, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AL	10-130201	05/19/98	JAPAN			
	AM	10-36272	02/10/98	JAPAN			
	AN	WO 96/40189	12/19/96	WIPO			
	AO	0 150 166	07/31/85	EUROPE			
	AP	639 573	02/22/95	EUROPE			
	AQ	639 572		EUROPE (corr. US 5,852,046)			
	AR	7-145149	1995	JAPAN (corr. US 5,852,046)			
	AS						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AT	J. N. M. GLOVER, et al., Letters To Nature, Vol. 373, No. 6511, pps. 257-261, "CRYSTAL STRUCTURE OF THE HETERODIMERIC bZIP TRANSCRIPTION FACTOR c-Fos-c-JUN BOUND TO DNA," January 19, 1995					
	AU	Y. NISHIBATA, et al., Tetrahedron, Vol. 47, No. 43, pps. 8985-8990, "AUTOMATIC CREATION OF DRUG CANDIDATE STRUCTURES BASED ON RECEPTOR STRUCTURE. STARTING POINT FOR ARTIFICIAL LEAD GENERATION," 1991					
	AV	Y. C. MARTIN, et al., Journal Of Medicinal Chemistry, Vol. 35, No. 12, pps. 2145-2154, "3D DATABASE SEARCHING IN DRUG DESIGN," June 12, 1992					
	AW	S. YAO, et al., Biopolymers, Vol. 47, No. 4, pps. 277-283, "UNCOILING C-JUN COILED COILS: INHIBITORY EFFECTS OF TRUNCATED FOS PEPTIDES ON JUN DIMERIZATION AND DNA BINDING IN VITRO," 1998					
	AX	M. CUSHMAN, et al., Journal of Medicinal Chemistry, Vol. 41, No. 12, pps. 2076-2089, "NEW ALKENYLDIARYLMETHANES WITH ENHANCED POTENCIES AS ANTI-HIV AGENTS WHICH ACT AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS," 1998					
	AY	N. NEAMATI, et al., Journal of Medicinal Chemistry, Vol. 40, No. 6, pps. 942-951, "DEPSIDES AND DEPSIDONES AS INHIBITORS OF HIV-1 INTEGRASE: DISCOVERY OF NOVEL INHIBITORS THROUGH 3D DATABASE SEARCHING," 1997					
	AZ	M. CUSHMAN, et al., Biochemical and Biophysical Research Communications, Vol. 185, No. 1, pps. 85-90, "INHIBITION OF HIV-1 INTEGRATION PROTEIN BY AURINTRICARBOXYLIC ACID MONOMERS, MONOMER ANALOGS, AND POLYMER FRACTIONS," May 29, 1992					
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

RECEIVED  
MAR 28 2002  
TECH CENTER 1600/2900

RECEIVED  
NOV 05 2002  
TECH CENTER 1600/2900